Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from SAVA

Unpacking the Latest Options Trading Trends in Cassava Sciences

Deep-pocketed investors have adopted a bullish approach towards Cassava Sciences (NASDAQ:SAVA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SAVA usually suggests something big is…

Benzinga

Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today

SAVA, ZM, KSS, RIVN, TSLA were among the trending stocks among investors on Monday Nov. 25, 2024.

Benzinga

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing.

Investors Business Daily

Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results

Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company"))), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer's disease (AD) dementia, today announced

Benzinga

A High-potential Bull Put Strategy on Cassava Sciences

This Bull Put strategy has a 76.9% chance of profiting, with a low risk/reward ratio!

Barchart

Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days

Cassava Sciences sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Worth It: SAVA

“The SAVA experience is what would happen if Apple and Tesla had a baby and that baby was into acid."

Marie Claire

Two-storey restaurant and gym plan to breathe new life into Ayrshire town centre

Planning documents say the proposal will ensure the long-vacant building is 'recycled for the common good.'

Daily Record

Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors

Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage.

Investors Business Daily

2 Stocks You Should Think About Shorting

Interest rate increases and consequent market volatility look all set to persist in light of the better-than-expected September employment figures. Since the outlook seems bleak for fundamentally weak stocks SoFi Technologies (SOFI) and Cassava Sciences (SAVA), one may consider selling them short. Continue reading….

StockNews.com

5 Stocks to Delete From Your Watchlist in Q4

The stock market has been experiencing wild swings this year, with inflation at a multi-decade high and the Fed aggressively raising interest rates to bring it under control. Amid rising recession worries, we think fundamentally weak stocks, Advanced Micro Devices (AMD), Block (SQ), Ginkgo Bioworks (DNA), Rocket Lab USA (RKLB),…

StockNews.com

Cassava Plummets After Refuting New Claims Around Data Tampering Investigation

Cassava refuted reports Friday that it received a "termination letter" from officials surrounding an investigation — and SAVA stock fell.

Investors Business Daily

Over $2 Million Bet On Cassava Sciences; 4 Stocks Insiders Are Buying

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Recap: Cassava Sciences Q1 Earnings

Cassava Sciences (NASDAQ:SAVA) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

What Are Whales Doing With Cassava Sciences

Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 25.46% on an annualized basis producing an average annual return of 37.25%. Currently, Cassava Sciences has a market capitalization of $844.87 million.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

$1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 19.11% on an annualized basis producing an average annual return of 32.41%. Currently, Cassava Sciences has a market capitalization of $874.09 million.

Benzinga

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after

Benzinga

Benzinga's Daily Brief On Trending Tickers For April 19, 2022: Plug Power, Twitter, Cassava Sciences And More

Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.

Benzinga

How Is The Market Feeling About Cassava Sciences Inc?

Cassava Sciences Inc's (NASDAQ:SAVA) short percent of float has fallen 3.25% since its last report. The company recently reported that it has 10.93 million shares sold short, which is 30.09% of all regular shares that are available for trading.

Benzinga

This Is What Whales Are Betting On Cassava Sciences

A whale with a lot of money to spend has taken a noticeably bullish stance on Cassava Sciences. Looking at options history for Cassava Sciences (NASDAQ:SAVA) we detected 14 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 29.74% on an annualized basis producing an average annual return of 43.85%. Currently, Cassava Sciences has a market capitalization of $1.54 billion.

Benzinga

Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 26.48% on an annualized basis.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.